Abstract
The development of food fortified with polyphenols and polyphenol-rich foods represents a novel approach to prevent or attenuate type 2 diabetes. It has been reported that type 2 diabetes may affect the pharmacokinetics of various drugs in several animal models. There is powerful evidence linking dietary polyphenols consumption with the risk factors defining type 2 diabetes, even if some opposite results occurred. This mini-review summarizes important advances on diabetes-associated changes in pharmacokinetics of natural polyphenols. The pharmacokinetic behavior between drugs and dietary polyphenols probably may be different due to (i) Ingested dose/amount per day. The dietary polyphenol intake per day is much higher than that of clinical drugs; (ii) Complexity of the components. Clinical drugs are well-characterized and typically small molecules. However, the polyphenols in diet are unimaginably complex; (iii) Interaction with food proteins. Although the effects of food proteins on the bioavailability of polyphenols are still not examined in much detail, direct binding interactions of polyphenols to proteins always occur; (iv) The most common polyphenols in the human diet have a low intrinsic activity and are poorly absorbed from the intestine, highly metabolized, or rapidly eliminated. Although there is very limited information available so far, it is proposed that type 2 diabetes influences the pharmacokinetic behavior of dietary polyphenols including: i) competition of glucose with polyphenols regarding binding to plasma proteins; ii) weakened non-covalent interaction affinities of plasma proteins for natural polyphenols due to protein glycation in type II diabetes; iii) the enhanced clearance of polyphenols in type 2 diabetes. An understanding of diabetes-associated changes in absorption, distribution, metabolism, elimination and bioactivities of natural polyphenols as well as the mechanism of the variability should lead to the improvement of the benefits of these polyphenols and clinical outcomes for diabetics.
Keywords: Metabolism, pharmacokinetic, polyphenols, type 2 diabetes.
Current Drug Metabolism
Title:Influence of Diabetes on the Pharmacokinetic Behavior of Natural Polyphenols
Volume: 15 Issue: 1
Author(s): Jianbo Xiao and Petra Hogger
Affiliation:
Keywords: Metabolism, pharmacokinetic, polyphenols, type 2 diabetes.
Abstract: The development of food fortified with polyphenols and polyphenol-rich foods represents a novel approach to prevent or attenuate type 2 diabetes. It has been reported that type 2 diabetes may affect the pharmacokinetics of various drugs in several animal models. There is powerful evidence linking dietary polyphenols consumption with the risk factors defining type 2 diabetes, even if some opposite results occurred. This mini-review summarizes important advances on diabetes-associated changes in pharmacokinetics of natural polyphenols. The pharmacokinetic behavior between drugs and dietary polyphenols probably may be different due to (i) Ingested dose/amount per day. The dietary polyphenol intake per day is much higher than that of clinical drugs; (ii) Complexity of the components. Clinical drugs are well-characterized and typically small molecules. However, the polyphenols in diet are unimaginably complex; (iii) Interaction with food proteins. Although the effects of food proteins on the bioavailability of polyphenols are still not examined in much detail, direct binding interactions of polyphenols to proteins always occur; (iv) The most common polyphenols in the human diet have a low intrinsic activity and are poorly absorbed from the intestine, highly metabolized, or rapidly eliminated. Although there is very limited information available so far, it is proposed that type 2 diabetes influences the pharmacokinetic behavior of dietary polyphenols including: i) competition of glucose with polyphenols regarding binding to plasma proteins; ii) weakened non-covalent interaction affinities of plasma proteins for natural polyphenols due to protein glycation in type II diabetes; iii) the enhanced clearance of polyphenols in type 2 diabetes. An understanding of diabetes-associated changes in absorption, distribution, metabolism, elimination and bioactivities of natural polyphenols as well as the mechanism of the variability should lead to the improvement of the benefits of these polyphenols and clinical outcomes for diabetics.
Export Options
About this article
Cite this article as:
Xiao Jianbo and Hogger Petra, Influence of Diabetes on the Pharmacokinetic Behavior of Natural Polyphenols, Current Drug Metabolism 2014; 15 (1) . https://dx.doi.org/10.2174/1389200214666131210142614
DOI https://dx.doi.org/10.2174/1389200214666131210142614 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Inflammation, Adiponectin, Obesity and Cardiovascular Risk
Current Medicinal Chemistry Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Overcoming Barriers to Evidence-Based Diabetes Care
Current Diabetes Reviews A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Research and Clinical Applications of Optical Coherence Tomography in Invasive Cardiology: A Review
Current Cardiology Reviews New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors
Current Pharmaceutical Design Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Aquaporin and Blood Brain Barrier
Current Neuropharmacology Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Inflammatory Cytokines and Cardiovascular Disease
Current Drug Targets - Inflammation & Allergy Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Neonatal Germ Cell Tumors
Current Pediatric Reviews Cognition and State Anxiety are Regulated by Thyroid Hormone Signaling
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets